Open Clinical Trials by Disease
For more information on clinical trials go to: clinicaltrials.gov
BILIARY TRACT
SWOG S1815 (NCT#03768414) Stage: III or IV
This trial shows how well gemcitabine and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Researchers are studying if giving gemcitabine and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers.
BLADDER
Alliance A031501 (NCT#03244384) Stage: T2 and/or N1 at surgical resection post neoadjuvant chemo; T3 or N1 at surgical resection with no neoadjuvant chemo
This randomized trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes. Pembrolizumab blocks the PD-1 axis and can interfere with the ability of tumor cells to grow.
BMS CA209-901 (NCT#03036098) Stage: IV or surgically unresectable
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating patients with previously untreated inoperable or metastatic urothelial cancer.
BREAST - ADJUVANT
AFT-27 WO39391 (NCT#03498716) Stage: II or III
This study will evaluate (after surgery) atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer).
Alliance A011502 (NCT#02927249) Stage: II or III
This randomized trial studies how well aspirin works in preventing the breast cancer from coming back in patients with negative human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.
Alliance A211601 (NCT#03609021) Stage: II or III & enrolling to A011502/ABC Trial
This phase III trial evaluates mammographic breast density in participants with hormone receptor-negative breast cancer enrolled on study A011502. High breast density has been shown to be a strong risk factor for developing breast cancer and decreasing breast density may decrease the risk for breast cancer. Participants treated with aspirin may show reduced breast density on a mammogram.
***only hormone receptor negative pts enrolling to A011502 are eligible***
CCTG MA39 (NCT#03488693) Stage: T1-2 & N1 & OncotypeDX <18
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
NSABP B51 RTOG 1304 Open via RT (NCT#01872975) Stage: T1-3 N1 before neoadjuvant chemo with neg nodes at surgery
This randomized trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.
SWOG S1418 (NCT#02954874) Stage: Completed chemo followed by surgery=residual disease found
This randomized trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
BREAST-DCIS
AFT-25 (NCT#02926911) Stage: DCIS (grade 1 or 2)
This study looks at the risks and benefits of active surveillance (observation) compared to guideline concordant care (surgery) in the setting of low risk DCIS. Researchers feel that management of low-risk Ductal Carcinoma in Situ (DCIS) using an active surveillance approach does not yield inferior cancer or quality of life outcomes compared to GCC.
BREAST - METASTATIC
Alliance A171601 (NCT#03633331) Stage: IV (1st or 2nd line) & age = > 70yo
This trial studies the side effects and how well palbociclib and letrozole or fulvestrant works in treating patients aged 70 years and older with estrogen receptor positive, HER2 negative breast cancer that has spread to other places in the body. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as letrozole or fulvestrant, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NRG BR004 (NCT#03199885) Stage: IV or Recurrent HER2+
This randomized trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with trastuzumab, pertuzumab, and atezolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill more tumor cells.
SWOG S1703 (NCT#03723928) Stage: IV
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be done may be as good as the usual approach to monitoring disease.
NRG-BR002 (NCT#02364557) Stage: IV
This randomized trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to minimal sites that are previously untreated. Researchers are looking to see if stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be able to effectively remove the metastatic tumor cells.
BREAST - OTHER
Alliance A011401 (NCT#02750826) Stage: II or III
This randomized trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back. Previous studies have found that women who are overweight or obese when their breast cancer is found have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.
CLL
ECOG-ACRIN EA9161 (NCT#03701282) Stage: No prior treatment & age </=70yo
This trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Alliance A041702 (NCT#03737981) Stage: No prior treatment & age </=70yo
This trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gastrointestinal
Alliance A021502 (NCT#02912559) Stage: Resected stage III colon cancer & abnormal IHC
This trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Researchers are studying the combination of chemotherapy with atezolizumab and whether it works better than combination chemotherapy alone in treating patients with colon cancer.
Alliance A021602 (NCT#03375320) Stage: Advanced Neuroendocrine Tumors after progression on Everolimus
This randomized trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
NRG-GI004 (NCT#02997228) Stage: Metastatic Colorectal Cancer w/ deficient DNA Mismatch repair
This randomized trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
LUNG CANCER - METASTATIC
SWOG (NCT#03851445) Stage: IV (2nd line)
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study). The type of cancer trait (biomarker) will determine to which sub-study a participant will be assigned.
SUB-STUDIES: S1800A (NCT# TBD), Non-match sub-study. A randomized study of Ramucircumab + MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP). S1900A (NCT#03845296), This trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
EA5163 (NCT#03793179) Stage: IV (1st line)
This trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.
LUNG CANCER – NON-SMALL CELL
A151216 (NCT#02194738) Stage: IB (if 4cm or greater), IIA, IIB, or IIIA
This trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
SUB-STUDIES: EA5142 (NCT#02595944), This phase trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. E4512 (NCT#02201992), This randomized trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. A081105 (NCT#02193282), This trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
A221504 (NCT#03087708) Stage: IIIB or IV
This randomized clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer.
LUNG CANCER - SMALL CELL
RTOG 0538 CALGB30610 (NCT#00632853) Stage: Limited
It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.
PROSTATE
AFT-19 (NCT#03009981) Stage: Prior prostatectomy with PSA doubling time 9 months or less
This is a randomized, open-label, three-arm, study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
NRG GU006 (NCT#03371719) Stage: III & IV
This trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer than radiation alone.
SWOG S1802 (NCT#03678025) Stage: IV
This trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
RENAL CELL
A031704 (NCT#03793166) Stage: IV
This trial studies how well nivolumab and ipilimumab, followed by nivolumab versus cabozantinib and nivolumab, work in treating patients with renal cell cancer that is untreated and has spread to other parts of the body. It is not yet known how well cabozantinib and nivolumab work in treating patients with untreated renal cell cancer that has spread to other parts of the body.
SOLID TUMOR (and LYMPHOMA/MYELOMA)
ECOG-ACRIN EAY131 (NCT#02465060) Stage: No other approved standard therapy available
The MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
VENOUS THROMBOEMBOLISM (VTE)
ACCRU SC-1601 (NCT#03080883) Stage: IV
This randomized trial studies the best dose of apixaban and how well it works in preventing secondary cancer related blood clots in cancer patients who have completed anticoagulation therapy. Apixaban may stop the clotting of blood by blocking some of the enzymes needed for blood clotting.
AFT-28 (NCT#02744092) Stage: Any Blood clot </=30 days
The objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin.